The U.S. Food and Drug Administration (FDA) recently approved a ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Xeris Pharmaceuticals is marketing this new glucagon injection as GVOKE. GVOKE is the first glucagon product approved that can be administered via...
Read MoreDimensions in Diabetes 2019, the 5th Annual Program of the Endocrine society in India, provides cutting-edge education to advance knowledge, and stay up to date with the latest evidence based strategies to improve diabetes practice.
Read MoreWhile clinical inertia exists, Henry Anhalt, DO says that when physicians listen to their patients with diabetes, it goes a long way towards getting the right treatment for each person.
Read MoreSpringtime in Washington, D.C., always includes cherry blossoms; bus loads of tourists visiting the national monuments, memorials, and museums; and groups who come to Capitol Hill to advocate on issues Congress is considering. The Endocrine Society is no exception.
Read MoreDr. Anhalt and the Panzirer Family discuss the exciting changes made possible due to scientific advances in cellular therapies.
Read MoreLearn about T1D Exchange's mission to improve the lives of people touched by type 1 diabetes by facilitating better care and accelerating new therapies. This mini-documentary brings together a variety of voices (clinical, research and patient) that express the very human side of T1D Exchange's mission and how we drive faster, better research to improve outcomes in type 1 diabetes.
Read MoreEndocrine Today | Research during the past few years has suggested that American girls are entering puberty earlier - some as young as 6 years of age. The phenomenon has been linked to specific pathologies, obesity and even environmental toxins. Fortunately, this problem has limited scope and there are ways to help children in early puberty.
Read MoreContinuing the conversation on Diabetes Medical Devices with our special guest: Dr. Henry Anhalt, Chief Medical Officer and Medical Director of the Artificial Pancreas Program for Animas Corporation is responsible for the company’s medical and clinical activities. His current area of focus is on the joint Juvenile Diabetes Research Foundation-Animas artificial pancreas project.
Read More
